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Abstract
Objective: Lassa fever (LF), a hemorrhagic fever endemic to West Africa, has an incidence of 
approximately 500,000 cases per year. This study evaluated hearing loss and other sequelae 
following LF.
Methods: This case–control study enrolled laboratory-confirmed LF survivors, non-LF febrile 
controls and matched-community controls with no history of LF or recent hospitalization for a 
febrile illness. Study participants completed a symptom questionnaire. Pure-tone audiometry was 
completed by a subset of participants.
Results: A total of 147 subjects aged 3–66 years (mean, 23.3) were enrolled. LF survivors were 
significantly more likely to report balance difficulties (55% vs. 20%, p < 0.001), hair loss (32% vs. 
7%, p < 0.001), difficulty speaking (19% vs. 1%, p < 0.001), social isolation (50% vs. 0%, p < 
0.001), and hearing loss (17% vs. 1%, p = 0.002) in comparison with matched-community 
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controls. Similar trends were noted in comparison with febrile controls, although these findings 
were non-significant. Fifty subjects completed audiometry. Audiometry found that LF survivors 
had significantly more bilateral hearing loss in comparison with matched-community controls 
(30% vs. 4%, p = 0.029).
Conclusion: This study characterized the sequelae of LF and highlighted the need for increased 
access to hearing care in West Africa.
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Introduction
According to data from the global burden of disease study, hearing loss is currently the 
second leading cause of years lived with a disability. Approximately 1.4 billion people, or 
18.7% of the world’s population, are currently living with hearing loss (James et al., 2018; 
Graydon et al., 2019). This burden is unequally distributed, with >80% of affected 
individuals residing in low-income and middle-income countries, where access to specialty 
care is often limited (Fagan and Jacobs, 2009; Graydon et al., 2019). Understanding the 
etiologies that are unique to these areas is critical to addressing this global disparity.
Viral hemorrhagic fevers represent an etiology of hearing loss, which contributes to this 
disproportionate burden. Lassa fever, a viral hemorrhagic fever endemic to Sierra Leone and 
the West African region, was first discovered in 1969 (Richmond and Baglole, 2003; Ogbu 
et al., 2007). Shortly thereafter, case reports documenting hearing loss associated with 
infection were published (White,1972). The acute phase of disease is characterized by a non-
specific febrile illness, which later evolves to include renal and hepatic dysfunction, 
conjunctivitis, severe pharyngitis, facial edema, hematemesis, pleural and pericardial 
effusion, and death (White, 1972; Richmond and Baglole, 2003; Okokhere et al., 2018). The 
case fatality rate of this disease is approximately 15–20% for the entire West African region. 
However, notable variations in mortality occur geographically (Shaffer et al., 2014). No 
incidence studies of Lassa fever currently exist. However, it is estimated that 250,000–
500,000 infections occur annually across Sub-Saharan Africa (Richmond and Baglole, 2003; 
Ogbu et al., 2007; Ibekwe, 2012). Although the majority of infections are asymptomatic or 
sub-clinical, it has been noted that approximately a third of Lassa fever infections result in 
chronic hearing loss (Mertens et al., 1972; Cummins et al., 1990; Ibekwe et al., 2011; 
Ibekwe, 2012; Yun et al., 2015; Okokhere et al., 2018). This associated prevalence is 
estimated to be 10–300 times greater than other more common viral etiologies of hearing 
loss (Cohen et al., 2014; Ficenec et al., 2019). Despite the strong association between Lassa 
fever and hearing loss, this and other sequelae remain poorly understood.
This case control study further characterizes the relationship between Lassa fever, hearing 
loss and other viral sequelae. Characterization of the full disease course, including 
convalescent symptoms, may help to identify risk factors for diagnosis, improve predictions 
of prognosis, and elucidate the mechanisms of disease pathogenesis. An increased 
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understanding of this disease allows for an improved ability to design interventions and 
treatments.
Methods
This study was conducted in eastern Sierra Leone from May 2007 to June 2009. The Lassa 
fever ward at Kenema Government Hospital (KGH) provided patient records from which 
eligible subjects were identified. Subjects were then located throughout the surrounding 
areas.
To ensure that findings were not merely a consequence of hospitalization and were specific 
to Lassa fever, three groups of individuals were enrolled: Lassa fever survivors, febrile 
controls, and matched-community controls. Lassa fever survivors were defined as 
individuals diagnosed by positive Lassa fever serology, clinical methods and hospitalized at 
KGH. Febrile controls were individuals who were hospitalized for a febrile illness at KGH 
and did not meet Lassa fever diagnostic criteria. All Lassa fever survivors and febrile 
controls were hospitalized and treated at KGH 3 months to 3 years prior to imitation of this 
study. An additional age-matched and gender-matched community control was recruited for 
each Lassa fever survivor and febrile control from the same or neighboring household.
Upon enrollment into the study, individuals completed questionnaires assessing 
constitutional, psychiatric, neurologic, ocular, otologic, vestibular, respiratory, cardiac, 
gastrointestinal, and musculoskeletal symptoms, as well as social stigma and fatigue. 
Audiometric exams were added to the study protocol in 2009 and completed by a subset of 
50 participating individuals. Pure-tone thresholds were measured across 0.5–4 kHz and were 
used to calculate a pure-tone average (PTA) for each ear. These mid-frequencies were 
chosen as they represent the majority of measured frequencies in the human speech 
spectrum and standard audiometric exams. Bilateral hearing loss was defined according to 
WHO standards as a PTA >25 dB in both ears. Individuals with a PTA >25 dB in a single ear 
were classified as having unilateral hearing loss.
All questionnaires and audiometry were completed in the participating individual’s language 
of choice. The questionnaires that were employed by this study were tested and verified by 
local volunteers for appropriate translation and cultural competency. Study personnel 
collecting data were blinded as to the status of study participants. Data were organized into 
frequency tables and tested for significance by ANOVA and Pearson’s Chi-squared tests, 
where appropriate. In order to account for the possibility of spurious relationships when 
making multiple comparisons, the alpha level required for significance was adjusted using 
Bonferroni corrections, where appropriate. The alpha level required for significance of Lassa 
fever symptoms and complaints was adjusted to 0.0023. The alpha levels required for 
significance of socio-economic and psychiatric complaints as well as audiometry data were 
not adjusted due to the small number of comparisons being made among these families of 
data. This study was approved by the Tulane University Institutional Review Board and the 
administrators of Kenema Government Hospital.
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A total of 147 subjects were enrolled in this study. Ages ranged from 3 to 66 years, with a 
median age of 21 years (Table 1). Sixty-six percent of subjects were adolescents and adults 
(≥15 years), 30% were school-age children (5–14 years), and 4% were aged <5 years. 
Approximately half (49.3%) of the enrolled subjects were men. The median age of the 
febrile control group (28 years) was slightly higher than that of the Lassa fever (21 years) 
and matched-community control (20 years) groups. However, this result was found to be 
non-significant (p = 0.224).
All 147 subjects enrolled in this study completed a symptom questionnaire (Table 2). A sub-
set of 50 individuals completed a socioeconomic and psychiatric symptom questionnaire 
(Table 3). In comparison with the matched-community control group, Lassa fever survivors 
were significantly more likely to report difficulties with balance (55.3% vs. 19.7%, p < 
0.001), hair loss (32% vs. 7%, p < 0.001), hearing loss (17% vs. 1%, p = 0.002), and 
difficulty speaking (19% vs. 1%, p < 0.001). Additionally, Lassa fever survivors were also 
significantly more likely to report social isolation (50.0% vs. 0%, p < 0.001) in comparison 
with matched-community controls. Likely due to the small sample sizes recruited for this 
study, Lassa fever survivors were not found to have significantly increased complaints of any 
symptom in comparison with the febrile controls. However, trends of increased weight loss 
(57% vs. 34%, p = 0.052), headaches (74% vs. 55%, p = 0.082) and hair loss (32% vs. 14%, 
p = 0.076) were found. Few differences in socio-economic and psychiatric complaints were 
noted (Table 3). The only significant difference found between Lassa fever survivors and 
febrile controls was a decreased prevalence of social embarrassment (30% vs. 73%, p = 
0.032), while only a sense of isolation was significantly more common among Lassa fever 
survivors and controls (50% vs. 0%, p < 0.001).
Audiometry was added to the study protocol in 2009 and was performed on a subsample of 
50 subjects participating in the study. This sample consisted of 10 Lassa fever survivors, 15 
febrile controls, and 25 matched-community controls. Audiometric tracings showed 
increased pure tone thresholds affecting low-frequency tones in each of the three groups 
(Figure 1); however, no significant difference was noted between any individually measured 
frequency (Table 4). Hearing loss in this study was defined as a PTA >25 dB. Overall, 18 
subjects were found to have either bilateral or unilateral hearing loss: four (40%) Lassa fever 
survivors, three (20%) febrile controls, and 11 (44%) matched-community controls (Table 
5). No significant differences in the prevalence of hearing loss were found between any of 
the three groups. However, Lassa fever survivors were more likely to have bilateral hearing 
loss in comparison with matched-community control subjects (30% vs. 4%, p = 0.029). 
When hearing loss was categorized by severity, 13 (26%) of 50 individuals had mild hearing 
loss, four (8%) had moderate hearing loss, none (0%) had severe hearing loss, and one (2%) 
was found to have profound hearing loss (Table 3). However, no significant differences were 
found in severity of hearing loss between the three groups. After controlling for age, the 
results were unchanged.
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This case–control study characterizes the long-term sequelae of Lassa fever by comparing 
the symptoms of survivors with febrile and matched-community control groups. It found 
that 17% of Lassa fever survivors had subjective hearing loss in comparison with 7% of 
febrile and 1% of matched-community controls. Subjective complaints have previously been 
demonstrated as a high sensitivity and specificity method of detecting hearing loss (Clark et 
al., 1991; Nondahl et al., 1998; Gomez et al., 2001; Sindhusake et al., 2001; Valete-rosalino 
and Rozenfeld, 2005). Audiometric exams demonstrated that 30% of Lassa fever survivors 
had bilateral hearing loss, which was significantly greater than the 4% prevalence exhibited 
by matched-community controls, with a trend of greater prevalence when compared with the 
7% of febrile controls. Vertigo and balance difficulties were also commonly noted among 
Lassa fever survivors, reported by 21% and 55% of the study population, respectively. In 
addition, Lassa fever survivors were more likely to complain of balance, hair loss, difficulty 
speaking, and social isolation in comparison with matched-community controls.
Typically, Lassa fever hearing loss is thought to occur during the convalescent stage of 
infection, arising within 5–22 days following the acute stage of illness. Among survivors of 
infection, it is estimated that a third may develop chronic hearing loss (Ficenec et al., 2019). 
This high prevalence would rank Lassa fever as one of the leading causes of viral mediated 
hearing loss, with a prevalence approximately 10–300 times greater than other viral causes. 
A 1990 case control study conducted in Sierra Leone examined the seropositivity of 32 
individuals known to have hearing difficulties within their respective communities. Of this 
group, 26 (81.2%) individuals were found to be seropositive for Lassa fever antibodies in 
comparison with six (18.7%) of those without hearing difficulties (Cummins et al., 1990). 
Of this group, half of the seropositive individuals reported awareness of any possible Lassa 
fever exposure. Which suggests that the Lassa fever virus is capable of inducing hearing loss 
in asymptomatic or mild infections and may represent a cause of an even greater proportion 
of hearing loss in West Africa.
Ribavirin, the only treatment available for Lassa fever, has been suspected as a possible 
cause of the associated hearing loss. However, several studies and reviews have found no 
association between the incidence of hearing loss and administration of ribavirin in Lassa 
fever patients (Mertens et al., 1972; White, 1972; Cummins et al., 1990; Macher and Wolfe, 
2006; Okokhere et al., 2009; Grahn et al., 2016; Mateer et al., 2018). Other mechanisms 
proposed for the pathogenesis of Lassa fever-associated hearing loss include direct viral 
damage, an immune-mediated response, and the development of subsequent vasculitis. 
Although evidence to support any of these theories is limited, past accounts have found 
gross and histopathology of blood vessels of non-human primates infected with the Lassa 
fever virus, which subsequently developed hearing loss to resemble that of an autoimmune 
vasculitis, specifically polyarteritis nodosa (Edington and White, 1972; Cashman et al., 
2018). Although there are no specific clinical tests to diagnose polyarteritis nodosa, the 
American College of Rheumatology has established a set of high specificity criteria (Table 
6). Fulfillment of at least three of these criteria is associated with high suspicion of diagnosis 
(Lightfoot et al., 1990). The Lassa fever survivors participating in the current study were 
significantly more likely than their matched-community controls to complain of increased 
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prevalence of unexplained weight loss, and polyneuropathies of peripheral and cranial 
nerves. These symptoms fit the three-criteria threshold establishing high suspicion of 
vasculitis. Furthermore, the known presence of renal, neurologic and gastrointestinal 
dysfunction during the acute phase of Lassa fever is in congruence with the symptoms of 
polyarteritis nodosa (Guillevin et al., 2005; Pagnoux et al., 2010). Additionally, the presence 
of hearing and hair loss in this study population supports the diagnosis of a systemic 
autoimmune disease (Parodi and Cozzani, 2014; Ralli et al., 2018). However, additional 
research is necessary in order to more fully support this hypothesis. An increased 
understanding of disease pathogenesis will allow for improved treatment and prevention 
methodologies for Lassa fever sequelae, with the ultimate goal of improving quality of life 
and reducing stigma in this population.
The study is the first to present audiometric data of Lassa fever survivors. Although, the 
presented audiometric data indicate that the majority of hearing loss in these cases is mild, 
this sequelae should not be discounted. Hearing loss and vestibular symptoms are well 
known to lead to decreased quality of life and socioeconomic status if left untreated. 
Previously, hearing loss has been associated with increased odds of under-employment or 
unemployment, lower socioeconomic status, increased risk of depression, social isolation, 
and an impairment in the ability to complete activities of daily living (Mulrow et al., 1990; 
Ruben, 2000; Dalton et al., 2003; Lasisi et al., 2007; Emmett and Francis, 2015). Children 
with untreated hearing loss have been shown to score lower on tests of cognitive ability and 
have lower longitudinal educational attainment (Wake et al., 2004; Teasdale and Sorensen, 
2007; Lieu, 2012; Emmett et al., 2015). This relationship between children with hearing loss 
and worse educational outcomes has also been associated with minimal or unilateral hearing 
loss (Bess et al., 1998; Lieu et al., 2010; Lieu, 2012). Survey data from Sierra Leone have 
indicated that financial constraints are a major deterrent for seeking care for diseases 
affecting the head and neck (Van Buren et al., 2014). However, treatment of hearing loss 
through the use of hearing aids or cochlear implants has been shown to be both cost-
effective and mitigate these long-term deficits (Tsakiropoulou et al., 2007; Baltussen and 
Smith, 2009; Baltussen et al., 2009; Tomblin et al., 2014; Dawes et al., 2015; Magro et al., 
2018; Vo et al., 2018). Due to these large quality of life and economic benefits, it is 
imperative that hearing loss screening and treatment programs for Lassa fever survivors and 
other individuals be initiated within West Africa. Especially, as modelling efforts predict a 
rising incidence in Lassa fever in the near future (Redding et al., 2016; Gibb et al., 2017).
Recent Lassa fever forecasting data have shown that due to global climate change, socio-
ecological changes in land use and human travel, disease incidence is likely to increase as 
more rodent species are found to be capable of transmitting the virus and the increased 
interaction between human and rodent species leads to increased spill-over events and 
disease transmission (Fichet-Calvet et al., 2007; Redding et al., 2016; Gibb et al., 2017). 
These predictions serve to strengthen recent calls to action, which establish Lassa fever as a 
priority disease for the scientific and medical community (Mehand et al., 2018). However, 
few of these predictive models have included any plan for the long-term management of the 
chronic sequelae resulting from infection.
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Future investigations of Lassa fever should include more detailed examinations of hearing 
loss and other inner ear disorders. Since the pathogenesis of this chronic sequelae is 
unknown, studies would benefit from the inclusion of a greater number of specific questions 
in order to identify symptomatology within organ systems. Understanding the true 
prevalence and mechanism of these disorders will aid in designing interventions to prevent 
the life-long effects of hearing loss and increase the quality of life among survivors of this 
neglected tropical disease. Although the results of this study are limited, due to small sample 
size and generalized symptom surveys, this data add to the current literature regarding Lassa 
fever, by defining hearing loss according to the WHO standards, reporting both subjective 
and objective measurements of hearing loss, and performing symptom surveys, which may 
aid in the delineation of the pathogenesis of chronic viral sequelae due to Lassa fever.
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Table 4
Mean pure tone thresholds of Lassa fever survivors and controls.
Mean pure tone thresholds (dB ± SE)
Frequency (kHz) Lassa (n = 10) Fever (n = 15) Control (n = 25)
p-value
a
0.25 27 ± 4 23 ± 4 27 ± 3 0.277
0.5
30 ± 5 21 ± 5 21 ± 2
28 ± 3 24 ± 3 29 ± 2 0.237
1
33 ± 4 23 ± 6 22 ± 2
21 ± 3 22 ± 3 26 ± 3 0.779
2
27 ± 4 21 ± 6 18 ± 2
17 ± 4 17 ± 4 20 ± 3 0.727
22 ± 4 22 ± 4 13 ± 1
4 19 ± 4 19 ± 4 22 ± 3 0.142
8
23 ± 5 23 ± 5 16 ± 2
24 ± 3 24 ± 3 25 ± 3 0.545
25 ± 6 25 ± 6 14 ± 2
Threshold values displayed with measurements from the left ear above the right ear.
a
One way ANOVA.
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